A Novel Necroptosis-Associated lncRNA Signature Can Impact the Immune Status and Predict the Outcome of Breast Cancer

Figure 11

Comparison of drug sensitivity between high-risk and low-risk groups. IC50 of paclitaxel (a), IC50 of CDK4/6 inhibitors (b), HDAC inhibitors (c), MEK inhibitors (d), PI3K inhibitors (e), and Akt inhibitors (f) in high-risk and low-risk populations.

(a)

(b)

(c)

(d)

(e)

(f)